2022
DOI: 10.1515/jpem-2022-0120
|View full text |Cite
|
Sign up to set email alerts
|

Novel non-stop variant of the NR0B1 gene in two siblings with adrenal hypoplasia congenita

Abstract: Objectives Mutations in the dosage-sensitive sex reversal-AHC critical region on the X chromosome, gene 1 (DAX-1, officially NR0B1), cause X-linked adrenal hypoplasia congenita (AHC) and hypogonadotropic hypogonadism (HHG). Salt-losing adrenal insufficiency usually occurs during the neonatal period or early childhood. We report a novel non-stop variant of NR0B1 in two siblings and their unusual clinical course. Case presentation … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“… 55 Another novel mutation of NR0B1 ( DAX-1 ) gene (p.*471K) was reported in two siblings with different clinical manifestations who inherited the mutation from their mother. 56 A novel frameshift mutation was described in adult X-linked onset congenital adrenal hypoplasia with delayed puberty in a male harboring NR0B1 gene : c.1034delC (exon 1). 57 Of note, a carrier of NROB1 variant experienced transitory central precocious puberty by the age of 11 months that remitted after hydrocortisone replacement for AD.…”
Section: Resultsmentioning
confidence: 99%
“… 55 Another novel mutation of NR0B1 ( DAX-1 ) gene (p.*471K) was reported in two siblings with different clinical manifestations who inherited the mutation from their mother. 56 A novel frameshift mutation was described in adult X-linked onset congenital adrenal hypoplasia with delayed puberty in a male harboring NR0B1 gene : c.1034delC (exon 1). 57 Of note, a carrier of NROB1 variant experienced transitory central precocious puberty by the age of 11 months that remitted after hydrocortisone replacement for AD.…”
Section: Resultsmentioning
confidence: 99%